Summit Therapeutics partners with Lunit on AI-powered tumor analysis for ivonescimab development
SMMT•Summit Therapeutics entered a research agreement with Lunit to evaluate Lunit’s AI-powered SCOPE IO pathology platform for ivonescimab development. The research will analyze tumor microenvironments in tissue images to support biomarker discovery, patient selection and clinical development planning.
1. Research agreement
Summit Therapeutics entered a research agreement with Lunit to evaluate the AI-powered SCOPE IO pathology platform for ivonescimab development. The research will analyze tumor microenvironments in tissue images to support biomarker discovery, patient selection and clinical development planning.
